JMI LABS IS NOW PART OF LEARN MORE

Filter by Event: Infectious Disease Society of America IDWeek 2016

Analysis of MIC Relationships Between Tedizolid, Linezolid, and Vancomycin Tested Against Staphylococcus aureus and Enterococcal Clinical Isolates from US and European Hospitals (2014-2015)

Analysis of MIC Relationships Between Tedizolid, Linezolid, and Vancomycin Tested Against Staphylococcus aureus and Enterococcal Clinical Isolates from US and European Hospitals (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1829

In Vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a US Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015)

In Vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a US Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1821

Activity of Pexiganan when Tested against Contemporary Gram-Positive, Gram-Negative Bacteria and Yeast Collected from North America, Europe and Japan

Activity of Pexiganan when Tested against Contemporary Gram-Positive, Gram-Negative Bacteria and Yeast Collected from North America, Europe and Japan, Lead author: Flamm, RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1826

Prevalence of Main Gram-positive Pathogens Causing Bloodstream Infections in US Medical Centers (2010-2015) and Analysis of Oritavancin In Vitro Activity

Prevalence of Main Gram-positive Pathogens Causing Bloodstream Infections in US Medical Centers (2010-2015) and Analysis of Oritavancin In Vitro Activity, Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 303

Activity of Omadacycline when Tested against Gram-Positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program

Activity of Omadacycline when Tested against Gram-Positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program, Lead author: Flamm, RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1827

Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015

Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015, Lead author: Flamm RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 2007

Activity of Isavuconazole and Comparator Mould-Active Triazoles Tested against Contemporary Invasive Mould Isolates

Activity of Isavuconazole and Comparator Mould-Active Triazoles Tested against Contemporary Invasive Mould Isolates, Lead author: Pfaller MA, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1621

In Vitro Activity of ZTI-01 (Fosfomycin for Injection) against Contemporary Gram-negative and Gram-positive Isolates – A Comparison of Inter-method Testing

In Vitro Activity of ZTI-01 (Fosfomycin for Injection) against Contemporary Gram-negative and Gram-positive Isolates – A Comparison of Inter-method Testing, Lead author: Flamm RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1833

Activity of Dalbavancin Tested against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014-2015)

Activity of Dalbavancin Tested against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1835

Dalbavancin In Vitro Activity Obtained against Gram-positive Clinical Isolates Causing Bone and Joint Infections in USA and European Hospitals (2011-2015)

Dalbavancin In Vitro Activity Obtained against Gram-positive Clinical Isolates Causing Bone and Joint Infections in USA and European Hospitals (2011-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1834

Next Generation Sequencing for Genomic Analysis of Cfr(B)-producing Enterococcus faecium Causing Infections in a New Orleans Medical Center

Next Generation Sequencing for Genomic Analysis of Cfr(B)-producing Enterococcus faecium Causing Infections in a New Orleans Medical Center, Lead author: Deshpande L, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1408

Evaluation of the In Vitro Activity of Ceftaroline Tested against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015)

Evaluation of the In Vitro Activity of Ceftaroline Tested against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1846

Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates

Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates, Lead author: Pfaller MA, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1625

Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from USA Hospitals Stratified by Site of Infection: Results from the INFORM Surveillance Program, 2013-2015

Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from USA Hospitals Stratified by Site of Infection: Results from the INFORM Surveillance Program, 2013-2015, Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1831

Ceftazidime-Avibactam Activity when Tested against Gram-negative Bacteria Isolated from Patients with Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015)

Ceftazidime-Avibactam Activity when Tested against Gram-negative Bacteria Isolated from Patients with Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1837

Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested against Gram-Negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015)

Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested against Gram-Negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 703

Antimicrobial Susceptibility of KPC-Producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015)

Antimicrobial Susceptibility of KPC-Producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015), Lead author: Castanheira M, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1850

Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates from Multiple Infection Sources

Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates from Multiple Infection Sources, Lead author: Shortridge D, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1824

Activity of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates

Activity of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates, Lead author: Shortridge D, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1823

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013)

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 786